Soleno Therapeutics Enters $100 Million Accelerated Share Repurchase Agreement

Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company focused on rare‑disease treatments, announced that its Board has authorized a share repurchase and that the company has entered into an Accelerated Share Repurchase Agreement (ASR) with Jefferies LLC to buy back $100 million of its common stock. The deal includes an initial payment of $100 million and the initial delivery of approximately 1,511,553 shares, based on the company’s closing price on November 10, 2025. The final number of shares to be repurchased will be determined by the volume‑weighted average price of Soleno’s common stock during the ASR term and includes adjustments per the agreement’s terms. Completion of the repurchase is expected in Q1 2026. CEO and Chairman Anish Bhatnagar said the move reflects his confidence in the company’s commercial launch of VYKAT XR, a therapy for hyperphagia associated with Prader‑Willi syndrome. Soleno reported profitability in Q3 2025 and believes its future cash‑generation profile is “significantly underappreciated” by the capital markets. The company cautions that forward‑looking statements in the release are subject to risks and uncertainties. #SolenoTherapeutics #ShareRepurchase #VYKATXR #RareDiseaseBiotech #SlimScan #GrowthStocks #CANSLIM